Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950609 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
A Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03950609 is a Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 126-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03950609, a Phase 2 study of Neuroendocrine Neoplasm and Advanced Carcinoid Tumor, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Lenvatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950609
The ClinicalTrials.gov registry entry for NCT03950609 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 6 other Neuroendocrine Neoplasm trials with a reported enrollment target (71% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT03950609 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03950609 about?
NCT03950609 is a clinical study titled "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors". This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the...
What is the current status of trial NCT03950609?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2019-07-30. Estimated completion is 2028-03-30.
What conditions does trial NCT03950609 study?
This clinical trial studies the following conditions: Neuroendocrine Neoplasm, Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia, Type 1, Unresectable Carcinoid Tumor.
What interventions are being tested in trial NCT03950609?
The interventions under investigation include: Everolimus (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT03950609?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03950609 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.